With a FDA phase 3 trial succeeding, there is a partner there 100% if they wanted it.
Financially it would mean giving up future cash flows, so SI will need to figure out the best path forward for shareholders. Do another cap raise (at a reasonable price) before partnering CHF, lower back pain... or partner pediatric aGVHD resolve the short term cash problem but give away future cash flows.
This is a long term investment, irrational decisions now can have a significant detrimental effect to the long term value of MSB.
More importantly though, the technology is being validated in FDA phase 3 clinical trials. MSB’s MSC technology is no longer a “dream”, it is now becoming reality. 2018 milestone year.
NIH sponsored 2b CHF LVAD trial up next.
With a FDA phase 3 trial succeeding, there is a partner there...
-
- There are more pages in this discussion • 2,925 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
0.025(1.47%) |
Mkt cap ! $2.207B | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.73 | $1.64 | $4.189M | 2.480M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31201 | $1.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 59276 | 6 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |